Oriomics Biotech: A Rising Star in Tumor Methylation-Based Screening on the Banks of the Qiantang River

In recent years, Qiantang New Area has attracted numerous innovative enterprises in the biopharmaceutical sector, leveraging its superior geographical location, policy support, and robust innovation ecosystem.ORIOMICS is one such example. Since its inception, ORIOMICS has focused on a cutting-edge technology in the global biopharmaceutical field—tumor methylation detection—which is regarded as a highly promising method for early cancer detection.

At ORIOMICS, VCBeat met with and interviewed Mr. Yu Shaohua, Co-founder and General Manager of the company. Mr. Yu’s desk was piled high with research reports on the tumor early screening market. Mr. Yu stated, “We are at the forefront of a major transformation in the tumor early screening industry. The dual drivers of technological innovation and market demand have brought us unprecedented growth opportunities. The innovative atmosphere in Qiantang New Area...”"Favorable policies and supportive measures have provided us with an ideal platform for development, and our tumor methylation detection technology is the core instrument revolutionizing cancer screening methods. We are committed to making tumor screening more efficient and accurate through leading methylation technology, truly serving public health."

ORIOMICS’s technological innovation stems from the detection of methylation biomarkers.Methylation modification is a key phenomenon in the regulation of gene expression. In the early stages of carcinogenesis, methylation changes in the genome demonstrate higher sensitivity than traditional biomarkers. Therefore, it holds unique advantages for early cancer detection.

ORIOMICS’ technical advantages are reflected not only in its advanced methylation detection technology, but also inOriomics-DLML: A Proprietary Dual-Layer Machine Learning Algorithm Developed In-House by the Company, this algorithm can accurately extract key diagnosticdiagnostic information. The first layer, based on a Bayesian model, effectively focuses on and amplifies low-frequency circulating tumor DNA (ctDNA) signals; the second layer employs a Hidden Markov Model to accurately identify tumor-associated signals. This unique two-tier algorithmic architecture significantly enhances the accuracy and stability of detection, providing robust technical support for cancer screening and establishing ORIOMICS as an industry leader in the field of early cancer screening and diagnosis.

“We aim to leverage this innovative methylation detection technology to reduce the risks of misdiagnosis and missed diagnosis, enabling more individuals to promptly identify potential tumor risks through simple screening methods, thereby improving survival rates, extending survival time, and enhancing quality of life."Mr. Yu, full of confidence,"said.

The global cancer screening market is in a period of rapid expansion. According to research by Bizwit Consultancy, the size of China's cancer screening market reached $23.3 billion in 2023, and the total value of the global market is projected to exceed hundreds of billions of dollars by 2030. Amidst this trend, ORIOMICS clearly recognizes the coexistence of opportunities and challenges in the market.

“Although the market prospects are broad, the complexity of cancer screening does indeed pose significant challenges,” Mr. Yu admitted. “Especially in the field of early screening, we not only need high sensitivity and specificity in technology, but also need to balance the convenience of testing and the controllability of costs.” Against this backdrop, ORIOMICS has positioned itself at the forefront of the tumor early screening industry by leveraging its leading methylation screening technology, combined with a user-friendly testing platform and supporting automated interpretation software.

ORIOMICS’s assessment of the tumor screening market can be summarized in two points:

1. Early detection is key to the prompt, effective treatment and control of tumors;

2. The combined detection of multi-dimensional biomarkers represents the future direction of development.

Mr. Yu emphasized, “Early screening for gastrointestinal tumors is our strategic priority. We will continue to increase R&D investment and optimize screening technologies, aiming not only to gain recognition in the Chinese market but also to promote them globally.”

Cancer Incidence in ChinaThe incidence rate remains persistently high, with gastrointestinal tumors (such as gastric cancer, esophageal cancer, and colorectal cancer) being particularly prominent. Patients are often diagnosed at intermediate or advanced stages, resulting in poor treatment outcomes. According to the “Analysis of the Epidemiology of Malignant Tumors in China in 2022” released by the National Cancer Center in March 2024, there were approximately 1.58 million new cases and 1.11 million deaths from digestive system tumors—including colorectal, gastric, liver, esophageal, and pancreatic cancers—in China in 2022, accounting for more than 40% of all cancer-related deaths.

Malignant tumors of the digestive system have become a major public health problem threatening the health of the Chinese population.As one of the regions with a high incidence of digestive system tumors, China urgently needs efficient and low-cost early screening methods. ORIOMICSIt keenly identified this market pain point and established gastrointestinal tumor screening as the company’s strategic priority.

Mr. Yu pointed out: “There is a general lack of effective screening methods for digestive system tumors. Traditional screening methods, such as tumorTumor markers, ultrasound, imaging, and endoscopy all have certain limitations. For instance, tumor markers such as alpha-fetoprotein (AFP) exhibit inadequate screening performance; ultrasound has poor sensitivity for detecting early-stage tumors and its results are highly operator-dependent. Although imaging and endoscopic examinations offer high accuracy, their complex procedures, high costs, and issues with patient compliance hinder their widespread adoption in general population health screenings.To address the aforementioned pain points, ORIOMICS’ methylation screening technology requires only one tube of blood to resolve these issues, undoubtedly providing a cost-effective, non-invasive, and easily scalable solution.”

“On the other hand, as the core of the systemic circulation, the liver maintains an extensive blood exchange network with the gastrointestinal tract. This anatomical configuration facilitates the detection of circulating tumor DNA from digestive system tumors”(ctDNA) provides a smooth pathway, enabling it to penetrate the circulatory system with relative ease. Given the unique biological characteristics of liver and digestive system tumors at the level of blood circulation,ORIOMICS has chosen gastrointestinal tumors as its strategic focus, a decision driven not only by market demand but also by a profound understanding of the company’s technological advantages.“Currently, the company has successfully developed ‘Liwei’an,’ an early screening product for liver cancer, and ‘Xiaoweian,’ a multi-cancer joint detection product for the five most common cancers of the digestive system, achieving positive market feedback.”

ORIOMICS’ rapid growth is attributable to its strong R&D team and efficient leadership.The company’s core technical team comprises experts from renowned medical schools and cancer centers in China and the United States, who possess profound academic expertise and extensive technical accumulation in fields such as molecular biology, statistical genetics, and computational biology.Successfully established a comprehensive technical system for precise locus screening and efficient ctDNA enrichment tailored to PCR platforms, and published multiple high-impact academic articles.

Mr. Yu Shaohua, General Manager, is a seasoned expert in the field of biomedicine. HeFirmly believing that only by forging an elite team with both combat effectiveness and innovation can one maintain a leading position in fierce market competition, Mr. Yu sees it as...Innovation is the core engine driving sustainable corporate development, while perseverance is the key to overcoming all obstacles and challenges.

According to Mr. Yu, ORIOMICS has adhered to the principle of placing R&D at the core of its corporate development and pursuing continuous innovation since its inception. Currently, the company has established a comprehensive R&D system and formed stable collaborative partnerships with numerous leading research institutions, Grade A tertiary hospitals, and renowned universities in China. In the field of tumor methylation screening technology, ORIOMICS has successfully applied for and obtained multiple invention patents, which not only demonstrate its technical prowess but also provide strong support for its market competitiveness. “We are fully aware that every product and technology must undergo rigorous clinical validation to ensure it delivers tangible benefits to patients,” emphasized Mr. Yu. “ORIOMICS will continue to expand our R&D team and attract more top-tier talent in the industry, providing a steady stream of momentum for the iterative innovation and sustainable development of our technologies.”

“In the future, ORIOMICS will continue to focus on early screening for gastrointestinal tumors and plans to further expand its detection scope to include other cancer types, such as lung cancer and thyroid cancer.” According to Mr. Yu, “Based on methylation screening technology, we are developing more innovative products to cover a broader range of cancer types, striving to contribute to China’s cancer prevention and control efforts. The company is committed to building a comprehensive health management system that integrates cancer screening with personalized health management, providing one-stop services from screening and diagnosis to prognosis assessment. Our goal is to enhance public health awareness, promote early prevention and intervention for cancer, and improve people’s quality of life.”

As an emerging force along the Qiantang River, ORIOMICS has established a foothold in the field of cancer screening, with the goal of becoming an industry leader.ORIOMICS is committed to driving innovation to promote the widespread adoption and development of early cancer screening technologies, safeguarding the health of every individual and family.